Analysis of aestheticians shows that the comprehensive score of the "old" drug metformin is better.

analysis published by Johns Hopkins University in the United States, the 1970s biptogenic compared with the existing second-generation sulfonyl diazepam, pyrethroid seine, grenadines and alpha-glucosinase inhibitors and other diabetes treatment drugs, the efficacy is equivalent, and the presence of other drugs may lead to weight gain, hypoglycemia and other problemsThe researchers analyzed the risks/benefits of oral type 2 diabetes treatments, including second-generation sulfonyl diazepam, bipyrinium diketone, grenadines and alpha-glucosideenzyme inhibitors, involving 216 clinical lysmic trials and group studiesThe study focused on end-point blood sugar control, not cardiovascular mortality or peripheral arterial diseaseThe results showed that most oral drugs, such as pyrethroids, metformin, sulfonate, improved blood sugar control to the same extent, grenadines and alpha-glucose enzyme inhibitors had a slightly weaker therapeutic effect; In addition to metformin, most oral anti-diabetic drugs will gain weight by 1 to 5 kg, patients receiving second-generation sulfonyl drug treatment, their mild and severe hypoglycemia attacks are more frequent, the risk is as high as 36%, and the risk of metformin is 21%, the risk of metformin is 24%; the incidence of gastrointestinal symptoms of metformin is higher than other drugs included in the analysis, but compared with other drugs, the evidence of increased lactose poisoning is lessThe team at Johns Hopkins University points out that the use of pyrethroid-type drugs, such as piglitazone, has the potential to increase the risk of congestive heart failure (CHF) or peripheral edemaPrevious studies have also obtained evidence of a potential link between pyrethroid syntones andheartattacksThe meta-analysis showed that the top three comprehensive scores of anti-diabetic drugs in the study were metformin, glipizide and glimeprid, which ranked the top threeGSheater, who led the study, noted that the lower-priced "old" drug metformin is ideal for most people with diabetes, and that the findings could be useful in alleviating the financial burden on millions of elderly diabetics, especially those without health insurance(Zhang Yu)